Many countries in Europe are now introducing screening for colorectal cancer [1]. This considerable investment adds to national economic burdens and must be audited to demonstrate that it is cost-effective, well-targeted and of high quality. Spending more money, having more doctors, admitting more patients or having a nearby "center of excellence" does not necessarily result in improved outcomes.
No takes yet. Share an insight, caveat, or question.
Rembacken et al. (2012) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: